Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

The depression treatment market is experiencing steady growth, driven by rising mental health awareness, increasing prevalence of depression, and advancements in novel therapies. The market is ...

NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a generative AI software leader in clinical trial analytics, announces its funded collaboration with ...

One in 20 U.S. adults experience seasonal depression, most often in winter. UVA professor Kim Penberthy shares self-care tips ...

Mizuho analyst Graig Suvannavejh lowered the firm’s price target on Neumora Therapeutics (NMRA) to $4 from $20 and keeps an Outperform rating ...

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the firm, ...

The many benefits of yoga range from improved flexibility, balance, and strength to mental health and stress relief. It can ...

Q4 2024 Earnings Call Transcript February 24, 2025 Operator: Good day, and thank you for standing by. Welcome to the Myriad ...

Around 21 million adults in the U.S. (8.4%) experienced a major depressive episode in 2023 and Medicare Part B recipients are ...

Imagine you have a plant that just won’t grow. You consider the various factors that could be causing the plant to struggle – ...

UZEDY is currently approved for use every one or two months as a subcutaneous long-acting injectable (LAI) for the treatment ...

Teva Pharmaceuticals (TEVA) and Medincell (MEDCL) announced that the supplemental New Drug Application sNDA for UZEDY extended-release ...